CRISPR Therapeutics CRSP Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $423.31M+21.8% | $347.56M+21.3% | $286.5M+48.0% | $193.62M-17.7% | $235.18M-21.1% | ||
| $2.02B+24.0% | $1.63B-0.1% | $1.63B+6.7% | $1.53B-5.7% | $1.62B+0.9% | ||
| $7.63M0.0% | $7.63M-4.7% | $8.01M0.0% | $8.01M0.0% | $8.01M-30.5% | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $6.58M-33.2% | $9.84M-26.4% | $13.38M+7.7% | $12.43M+0.8% | $12.33M+48.4% | ||
| $2.45B+23.3% | $1.99B+2.9% | $1.93B+11.3% | $1.73B-7.2% | $1.87B-3.6% | ||
| $112.18M-3.2% | $115.85M-4.1% | $120.83M-3.3% | $124.93M-3.5% | $129.43M-3.5% | ||
| $128.67M-2.3% | $131.72M-2.2% | $134.66M-2.2% | $137.64M-1.9% | $140.28M-2.2% | ||
| $28.98M+18.9% | $24.37M+0.2% | $24.31M-4.6% | $25.47M+22.6% | $20.78M+31.3% | ||
| $2.73B+20.3% | $2.27B+0.9% | $2.25B+10.6% | $2.03B-6.3% | $2.17B-3.4% | ||
| $13.65M+22.5% | $11.14M-5.6% | $11.8M+21.0% | $9.75M-25.3% | $13.06M-11.2% | ||
| $13.11M0.0% | $13.11M— | $0— | $0— | $0-100% | ||
| $15.34M-2.7% | $15.77M+1,118% | $1.3M-39.2% | $2.13M-29.5% | $3.02M-21.4% | ||
| $18.61M+0.2% | $18.58M+1.8% | $18.26M+1.3% | $18.03M+3.0% | $17.51M+1.3% | ||
| $638K-42.7% | $1.11M-67.5% | $3.43M+379% | $715K-42.4% | $1.24M+175% | ||
| $136.29M-8.6% | $149.12M+25.4% | $118.96M+14.0% | $104.36M-12.6% | $119.45M+36.1% | ||
| $585.47M— | $0— | —— | —— | —— | ||
| $183.56M-2.4% | $188.17M-2.4% | $192.77M-2.4% | $197.43M-2.2% | $201.85M-2.2% | ||
| $5.95M-3.2% | $6.14M+16.4% | $5.28M+17.9% | $4.48M+34.8% | $3.32M-3.6% | ||
| $911.26M+165% | $343.43M+4.3% | $329.33M+3.4% | $318.59M-5.4% | $336.94M+8.7% | ||
| $3.12M+0.9% | $3.09M+2.5% | $3.01M+7.8% | $2.79M+2.7% | $2.72M+0.9% | ||
| $3.88B+0.6% | $3.86B+3.7% | $3.72B+9.1% | $3.41B+2.7% | $3.32B+0.9% | ||
| -$2.07B-6.3% | -$1.95B-7.2% | -$1.82B-6.2% | -$1.71B-13.9% | -$1.5B-10.0% | ||
| -$1.94M-140% | $4.82M-3.3% | $4.99M+23.4% | $4.04M-2.3% | $4.14M+125% | ||
| $60K0.0% | $60K0.0% | $60K-3.2% | $62K0.0% | $62K0.0% | ||
| $1.81B-5.6% | $1.92B+0.3% | $1.92B+12.0% | $1.71B-6.5% | $1.83B-5.3% | ||
| $2.73B+20.3% | $2.27B+0.9% | $2.25B+10.6% | $2.03B-6.3% | $2.17B-3.4% | ||
| $2.02B+24.0% | $1.63B-0.1% | $1.63B+6.7% | $1.53B-5.7% | $1.62B+0.9% | ||
| $28.98M+18.9% | $24.37M+0.2% | $24.31M-4.6% | $25.47M+22.6% | $20.78M+31.3% | ||
| $128.67M-2.3% | $131.72M-2.2% | $134.66M-2.2% | $137.64M-1.9% | $140.28M-2.2% | ||
| $128.67M-2.3% | $131.72M-2.2% | $134.66M-2.2% | $137.64M-1.9% | $140.28M-2.2% | ||
| $28.98M+18.9% | $24.37M+0.2% | $24.31M-4.6% | $25.47M+22.6% | $20.78M+31.3% | ||
| $128.67M-2.3% | $131.72M-2.2% | $134.66M-2.2% | $137.64M-1.9% | $140.28M-2.2% | ||
| $28.98M+18.9% | $24.37M+0.2% | $24.31M-4.6% | $25.47M+22.6% | $20.78M+31.3% | ||
| $74.93M-16.2% | $89.41M+6.2% | $84.18M+14.2% | $73.74M-12.9% | $84.62M+106% | ||
| $74.93M-16.2% | $89.41M+6.2% | $84.18M+14.2% | $73.74M-12.9% | $84.62M+106% | ||
| $13.11M0.0% | $13.11M— | $0— | $0— | $0-100% | ||
| $787.64M+281% | $206.75M-2.0% | $211.02M-2.1% | $215.45M-1.8% | $219.36M-1.9% | ||
| $3.88B+0.6% | $3.86B+3.7% | $3.72B+9.1% | $3.41B+2.7% | $3.32B+0.9% | ||
| $3.12M+0.9% | $3.09M+2.5% | $3.01M+7.8% | $2.79M+2.7% | $2.72M+0.9% | ||
| $60K0.0% | $60K0.0% | $60K-3.2% | $62K0.0% | $62K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CRISPR Therapeutics's total assets?
- CRISPR Therapeutics (CRSP) holds $2.7B in total assets, up 25.8% year over year.
- How much debt does CRISPR Therapeutics have?
- CRISPR Therapeutics carries $787.6M in total debt against $1.8B of shareholders' equity, a debt-to-equity ratio of 0.43.
- How much cash does CRISPR Therapeutics have?
- CRISPR Therapeutics holds $423.3M in cash and equivalents.
- Can CRISPR Therapeutics cover its short-term obligations?
- Its current ratio is 17.96 — current assets exceed current liabilities.
- Where does CRISPR Therapeutics's balance sheet data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
